Induced pluripotent stem cells (iPSCs) have emerged as a transformative technology in regenerative medicine, drug discovery, and biotechnology. Their ability to be derived from somatic cells and reprogrammed into a pluripotent state—capable of differentiating into virtually any cell type—has opened new frontiers in science and healthcare. As a result, the iPSCs market has been experiencing rapid growth, driven by increasing research applications, advancements in cellular therapies, and rising investment in biotechnology.
The global iPSCs market has been expanding steadily, with projections indicating substantial growth over the next decade. This surge is fueled by a combination of technological advancements, the need for better disease models, and the promise of personalized medicine. Key players in this market include biotechnology firms, pharmaceutical companies, research institutes, and academic organizations.
The iPSCs market can be segmented by: